Cargando…

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies

Though advanced cancers generally display complex molecular portfolios, there is a subset of patients whose malignancies possess only one genomic alteration or alterations in one oncogenic pathway. We assess how N-of-One therapeutic strategies impact outcomes in these patients. From 12/2012 to 9/201...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Diviya, Kurzrock, Razelle, Lee, Suzanna, Okamura, Ryosuke, Lim, Hyo Jeong, Kim, Ki Hwan, Sicklick, Jason K., Kato, Shumei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960821/ https://www.ncbi.nlm.nih.gov/pubmed/35347205 http://dx.doi.org/10.1038/s41698-022-00259-7

Ejemplares similares

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary
por: Kato, Shumei, et al.
Publicado: (2021)

Targeting G(1)/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
por: Kato, Shumei, et al.
Publicado: (2021)

Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience
por: Bohan, Sandy S., et al.
Publicado: (2020)

Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience
por: Louie, Bryan H., et al.
Publicado: (2022)

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐free DNA in invasive gliomas after treatment
por: Okamura, Ryosuke, et al.
Publicado: (2021)

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
por: Louie, Bryan H., et al.
Publicado: (2022)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response
por: Persha, Hanna E., et al.
Publicado: (2022)

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
por: Kato, Shumei, et al.
Publicado: (2020)

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real‐world precision‐medicine population
por: Rosenberg, Shai, et al.
Publicado: (2023)

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies
por: Kato, Shumei, et al.
Publicado: (2019)

Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
por: Shaya, Justin, et al.
Publicado: (2023)

Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden
por: Bieg‐Bourne, Cheyennedra C., et al.
Publicado: (2020)

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
por: Miyashita, Hirotaka, et al.
Publicado: (2023)

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken
por: Nikanjam, Mina, et al.
Publicado: (2022)

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
por: Patel, Hitendra, et al.
Publicado: (2019)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
por: Krishnamurthy, Nithya, et al.
Publicado: (2022)

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies
por: Goodman, Aaron M., et al.
Publicado: (2017)

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
por: Kato, Shumei, et al.
Publicado: (2020)

The Conundrum of Genetic “Drivers” in Benign Conditions
por: Kato, Shumei, et al.
Publicado: (2016)

Targeting the FGF/FGFR axis and its co-alteration allies
por: Uehara, Y., et al.
Publicado: (2022)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies
por: Shayeb, Akram Mesleh, et al.
Publicado: (2023)

Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics
por: Jardim, Denis L., et al.
Publicado: (2021)

Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies
por: Kato, Shumei, et al.
Publicado: (2018)

Real‐World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim‐Chester Disease
por: Saunders, Ila M., et al.
Publicado: (2019)

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
por: Kato, Shumei, et al.
Publicado: (2019)

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
por: Cohen, Philip R., et al.
Publicado: (2017)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients
por: Charo, Lindsey M., et al.
Publicado: (2020)

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
por: Sicklick, Jason K., et al.
Publicado: (2019)

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study
por: Sicklick, Jason K., et al.
Publicado: (2021)

MHC-I genotype and tumor mutational burden predict response to immunotherapy
por: Goodman, Aaron M., et al.
Publicado: (2020)

Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
por: Adashek, Jacob J., et al.
Publicado: (2020)

One-Month Outcomes of Cases Receiving Ticagrelor after Percutaneous Coronary Intervention; a Case Series
por: Namazi, Mohammad Hasan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vkkp3l99ke28bpihma163lig2t